Current questions in HIV-associated lung cancer

Marina Shcherba, Jonathan Shuter, Missak Haigentz

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: In this review, we explore current questions regarding risk factors contributing to frequent and early onset of lung cancer among populations with HIV infection, treatment, and outcomes of lung cancer in HIV-infected patients as well as challenges in a newly evolving era of lung cancer screening. RECENT FINDINGS: Lung cancer, seen in three-fold excess in HIV-infected populations, has become the most common non-AIDS defining malignancy in the highly active antiretroviral therapy era. HIV-associated lung cancer appears to be associated with young age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. There is no unified explanation for these observations, and aside from traditional risk factors, HIV-related immunosuppression and biological differences might play a role. In addition to smoking cessation interventions, screening and early cancer detection in HIV-infected populations are of high clinical importance, although evidence supporting lung cancer screening in this particularly high-risk subset is currently lacking, as are prospective studies of lung cancer therapy. SUMMARY: There is an urgent need for prospective clinical trials in HIV-associated lung cancer to improve understanding of lung cancer pathogenesis and to optimize patient care. Several clinical trials are in progress to address questions in cancer biology, screening, and treatment for this significant cause of mortality in persons with HIV infection.

Original languageEnglish (US)
Pages (from-to)511-517
Number of pages7
JournalCurrent Opinion in Oncology
Volume25
Issue number5
DOIs
StatePublished - Jan 1 2013

Fingerprint

Lung Neoplasms
HIV
Early Detection of Cancer
HIV Infections
Clinical Trials
Population
Highly Active Antiretroviral Therapy
Smoking Cessation
Immunosuppression
Patient Care
Smoking
Prospective Studies
Mortality
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shcherba, Marina ; Shuter, Jonathan ; Haigentz, Missak. / Current questions in HIV-associated lung cancer. In: Current Opinion in Oncology. 2013 ; Vol. 25, No. 5. pp. 511-517.
@article{4cd8aa4a8eeb44f6828162b230eebd0b,
title = "Current questions in HIV-associated lung cancer",
abstract = "PURPOSE OF REVIEW: In this review, we explore current questions regarding risk factors contributing to frequent and early onset of lung cancer among populations with HIV infection, treatment, and outcomes of lung cancer in HIV-infected patients as well as challenges in a newly evolving era of lung cancer screening. RECENT FINDINGS: Lung cancer, seen in three-fold excess in HIV-infected populations, has become the most common non-AIDS defining malignancy in the highly active antiretroviral therapy era. HIV-associated lung cancer appears to be associated with young age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. There is no unified explanation for these observations, and aside from traditional risk factors, HIV-related immunosuppression and biological differences might play a role. In addition to smoking cessation interventions, screening and early cancer detection in HIV-infected populations are of high clinical importance, although evidence supporting lung cancer screening in this particularly high-risk subset is currently lacking, as are prospective studies of lung cancer therapy. SUMMARY: There is an urgent need for prospective clinical trials in HIV-associated lung cancer to improve understanding of lung cancer pathogenesis and to optimize patient care. Several clinical trials are in progress to address questions in cancer biology, screening, and treatment for this significant cause of mortality in persons with HIV infection.",
author = "Marina Shcherba and Jonathan Shuter and Missak Haigentz",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/CCO.0b013e328363dfdb",
language = "English (US)",
volume = "25",
pages = "511--517",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Current questions in HIV-associated lung cancer. / Shcherba, Marina; Shuter, Jonathan; Haigentz, Missak.

In: Current Opinion in Oncology, Vol. 25, No. 5, 01.01.2013, p. 511-517.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current questions in HIV-associated lung cancer

AU - Shcherba, Marina

AU - Shuter, Jonathan

AU - Haigentz, Missak

PY - 2013/1/1

Y1 - 2013/1/1

N2 - PURPOSE OF REVIEW: In this review, we explore current questions regarding risk factors contributing to frequent and early onset of lung cancer among populations with HIV infection, treatment, and outcomes of lung cancer in HIV-infected patients as well as challenges in a newly evolving era of lung cancer screening. RECENT FINDINGS: Lung cancer, seen in three-fold excess in HIV-infected populations, has become the most common non-AIDS defining malignancy in the highly active antiretroviral therapy era. HIV-associated lung cancer appears to be associated with young age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. There is no unified explanation for these observations, and aside from traditional risk factors, HIV-related immunosuppression and biological differences might play a role. In addition to smoking cessation interventions, screening and early cancer detection in HIV-infected populations are of high clinical importance, although evidence supporting lung cancer screening in this particularly high-risk subset is currently lacking, as are prospective studies of lung cancer therapy. SUMMARY: There is an urgent need for prospective clinical trials in HIV-associated lung cancer to improve understanding of lung cancer pathogenesis and to optimize patient care. Several clinical trials are in progress to address questions in cancer biology, screening, and treatment for this significant cause of mortality in persons with HIV infection.

AB - PURPOSE OF REVIEW: In this review, we explore current questions regarding risk factors contributing to frequent and early onset of lung cancer among populations with HIV infection, treatment, and outcomes of lung cancer in HIV-infected patients as well as challenges in a newly evolving era of lung cancer screening. RECENT FINDINGS: Lung cancer, seen in three-fold excess in HIV-infected populations, has become the most common non-AIDS defining malignancy in the highly active antiretroviral therapy era. HIV-associated lung cancer appears to be associated with young age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. There is no unified explanation for these observations, and aside from traditional risk factors, HIV-related immunosuppression and biological differences might play a role. In addition to smoking cessation interventions, screening and early cancer detection in HIV-infected populations are of high clinical importance, although evidence supporting lung cancer screening in this particularly high-risk subset is currently lacking, as are prospective studies of lung cancer therapy. SUMMARY: There is an urgent need for prospective clinical trials in HIV-associated lung cancer to improve understanding of lung cancer pathogenesis and to optimize patient care. Several clinical trials are in progress to address questions in cancer biology, screening, and treatment for this significant cause of mortality in persons with HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=84883242187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883242187&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328363dfdb

DO - 10.1097/CCO.0b013e328363dfdb

M3 - Review article

VL - 25

SP - 511

EP - 517

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -